Published: Jul 06, 2021 By Vanessa Doctor, RN
Peter Macdiarmid/Getty Images
Global clinical research organization
PAREXEL International has agreed to be taken over from Pamplona Capital Management for $8.5 billion. Upon completion of the
merger, Parexel will be owned by EQT IX Fund and the private equity business within Goldman Sachs Asset Management.
Parexel is dually headquartered in Newton and Durham, North Carolina and specializes in developing new innovations in medicine to improve patient health. It engages in decentralized clinical trials, regulatory consultations, and leveraging insights from data. The definitive agreement is still subject to compliance conditions and other customary factors.
The merger with EQT, a global purpose-driven investment firm, adds to Parexel s pharmacological research capabilities. EQT has over € 67 billion (approx.. $79.2 billion) in assets under management spread out across 26 active funds. Its holdings have portfolios
amiFebruary 6, 2021 25
Every year the life science industry witnesses a global increase in the number of clinical trials. The increase in the number of clinical trials carried out can be due to factors such as the rapidly rising geriatric numbers across the developed and emerging regions, growing incidence of chronic diseases, the expiry of breakthrough medications, the scarcity of government funding for clinical trials and fierce competition in the pharmaceutical industry amongst others. As of December, 2017, 260,848 clinical trials were registered around the globe.
Market players have implemented a range of growth strategies, such as product launches, strategic acquisitions, alliances, partnerships, collaborations and expansions, to boost their product portfolios and maintain a competitive position in the clinical trials management system market. Among those business strategies, product improvements, agreements and alliances were the growth strategy most widely adopted by the
Calyx spins off medical imaging, eClinical solutions firm Formerly Parexel Informatics, the renamed clinical research technology company has broken off and will operate as an independent company going forward.
Calyx a UK-based company offering medical imaging, eClinical and regulatory services to clinical research clients has shed the name Parexel Informatics in favor of its new moniker. After this strategic separation, the company will continue its work pursuing innovative technology intended to accelerate the discovery and development of new treatments.
With 250 new drug approvals in its history, Calyx has supported over 25,000 trials involving more than fourteen million patients. The company will continue its focus on providing innovative technology solutions and services to speed the discovery of new treatments.